ALDH1A3 responded to androgen dihydrotestosterone treatment and increased the oxidation of retinal to RA in human prostate cancer cells [34], and was supposed to be the predominant isoenzyme responsible for ALDH activity and tumorigenicity in most NSCLC [38]. Here, ALDH1A3 is linked to prostate carcinoma.